ArticleFrontiers in immunology2025
Identification of lipid metabolism related immune markers in atherosclerosis through machine learning and experimental analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Inflammation and Immune Mechanisms in Atherosclerosis.Reviews in cardiovascular medicine · 2026Review
- Transcriptomic Analysis Reveals PACS1 as a Potential Shared Candidate Biomarker for Apical Periodontitis and Osteoporosis.International journal of molecular sciences · 2026Article
- Multi-layer network biology combined with single-cell evidence reveals core regulatory nodes in atherosclerotic plaques and potential drug-targeting directions.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Associations of Lipid and Adiposity Indices with Vascular Aging Stages in a Multicenter Chinese Population.Current medical science · 2026Article
- Identification of hub targets involved in carotid atherosclerosis through bioinformatics and machine learning approaches.BMC cardiovascular disorders · 2026Article
- Molecular Subtyping Based on EGFR Mutation-Associated Genes and the Prognostic Role of TRAF2 in Lung Adenocarcinoma.Human mutation · 2026Article
- Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction.Pharmaceutics · 2025Review
- Relationship between amino acid metabolism and inflammation in coronary heart disease (Review).International journal of molecular medicine · 2025Review
- Targeted drug delivery systems for atherosclerosis.Journal of nanobiotechnology · 2025Review
- TNF superfamily molecules in atherosclerosis: mechanistic insights and therapeutic translation.Frontiers in immunology · 2025Review
- Exploring the Molecular Functions and Immune Relevance of Macrophage-Associated Genes in Atherosclerosis.Human mutation · 2025Article
- The Role of MAPK12 in Prognosis of Patients With Liver Cancer and Effects on Stemness Characteristics.Stem cells international · 2025Article
- Integration of Immune Cell Signatures and Diagnostic Gene Markers in Pancreatitis: A Comprehensive Study on Therapeutic Targets and Predictive Diagnosis.Human mutation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerosis is a significant contributor to cardiovascular disease, and conventional diagnostic methods frequently fall short in the timely and accurate detection of early-stage atherosclerosis. Abnormal lipid metabolism plays a critical role in the development of atherosclerosis. Consequently, the identification of new diagnostic markers is essential for the precise diagnosis of this condition. Method: The datasets related to atherosclerosis utilized in this research were obtained from the GEO database (GSE2470, GSE24495, GSE100927 and GSE43292). The ssGSEA technique was first utilized to assess lipid metabolism scores in samples affected by atherosclerosis, thereby aiding in the discovery of important regulatory genes linked to lipid metabolism via WGCNA. Following this, differential expression analysis and functional evaluations were carried out, after which various machine learning approaches were employed to determine significant diagnostic genes for atherosclerosis. A diagnostic model was then developed and validated through several machine learning algorithms. Furthermore, molecular docking studies were conducted to analyze the binding affinity of these key markers with therapeutic agents for atherosclerosis. The ssGSEA technique was also used to measure immune cell scores in atherosclerotic samples, aiding the exploration of the connection between key diagnostic markers and immune cells. Finally, the expression variations of the identified pivotal genes were confirmed through experimental validation. Result: WGCNA identified 302 lipid metabolism-related genes in atherosclerotic samples, and functional analysis revealed that these genes are associated with multiple immune pathways. Through further differential analysis and screening using machine learning algorithms, APLNR, PCDH12, PODXL, SLC40A1, TM4SF18, and TNFRSF25 were identified as key diagnostic genes for atherosclerosis. The diagnostic model we constructed was confirmed to predict the occurrence of atherosclerosis with high accuracy, and molecular docking studies indicated that these six key diagnostic genes have potential as drug targets. Additionally, the ssGSEA algorithm further validated the association of these diagnostic genes with various immune cells. Finally, the expression levels of these six genes were experimentally confirmed. Conclusion: Our study introduces novel lipid metabolism-related diagnostic markers for atherosclerosis and emphasizes their potential as immune-related drug targets. This research provides a valuable approach for the predictive diagnosis and targeted therapy of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.